ArticleBiology direct2026
Multi-omics reveals fibroblast subtypes with distinct roles in inflammatory bowel disease.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundInflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract involving complex interactions among epithelial, immune, and stromal components. Fibroblasts are key regulators of intestinal inflammation and fibrosis, but their heterogeneity, distribution, and therapeutic potential remain unclear.
methodsWe systematically identified and characterized intestinal fibroblast subtypes in IBD while exploring the intercellular communication between fibroblasts and immune cells through the integration of single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) analyses. Functional gene signatures derived from fibroblast subtypes were applied to bulk RNA-seq datasets to predict therapeutic responses using logistic regression and random forest models. Concurrently, pertinent findings were validated in the intestinal tissues and primary fibroblasts of patients with IBD using multiplex immunohistochemistry (mIHC), western blotting, and quantitative real-time PCR (qPCR).
resultsWe identified 10 distinct stromal subpopulations comprising two fibroblast subtypes strongly associated with IBD pathology: ICAM1
conclusionsThis study provides a comprehensive characterization of fibroblast heterogeneity in IBD, highlighting the crucial roles of inflammatory and fibrotic fibroblast subsets as key mediators of immune-stromal interactions and potential predictors of therapeutic responsiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.